Research Reference
Wolverine Blend
Popular BPC-157 + TB-500 healing blend
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Wolverine is a grey-market peptide blend commonly combining BPC-157 and TB-500 (Thymosin Beta-4) marketed for recovery. Blend composition varies by source; it is not FDA approved.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 250 mcg | 5 units | 0.05 mL | SubQ, dailyCommunity recovery protocol |
| 500 mcg | 10 units | 0.1 mL | SubQ, dailyCommunity higher dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Wolverine Blend is a compounded combination peptide product marketed for tissue repair/recovery, typically combining BPC-157 and TB-500 (TB-4). The exact ratio varies by compounding pharmacy. It is sold as a lyophilized vial. It is not FDA-approved.
For a compounded 10 mg (total peptide) vial reconstituted with 2 mL, the concentration is 5 mg/mL; a 250 mcg dose draws to 5 units (0.05 mL) on a U-100 syringe. Store per compounding pharmacy directions; compounded forms are not FDA-approved.
Cycling Protocol
Community protocols describe Wolverine Blend injected subcutaneously daily for 4–8 weeks, sometimes cycled. No standardized cycle is established; Wolverine Blend is a compounded combination and not FDA-approved.
Routes of Administration
Subcutaneous injection (community): Into the abdomen, daily.
No oral or intranasal route is established for the injectable form. Wolverine Blend is not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Recovery Stack | Wolverine Blend + GHK-Cu | Community tissue-repair protocol (not established) |
Wolverine Blend is a compounded combination (BPC-157 + TB-500); composition varies by pharmacy. It is not FDA-approved.
Side Effects & Safety
- Injection-site reactions — common
- Depends on components — safety profile depends on BPC-157 and TB-500 components
- No FDA safety review — Wolverine Blend is compounded and not FDA-approved
Wolverine Blend is a compounded combination product, not FDA-approved. Composition varies by pharmacy; safety and efficacy have not been FDA-reviewed.
Research Basis
Wolverine Blend is a compounded combination peptide product marketed for tissue repair/recovery, typically combining BPC-157 and TB-500 (thymosin beta-4); composition varies by compounding pharmacy.
Mechanism: Depends on components; BPC-157 is described as supporting angiogenesis and tissue repair, TB-500 as supporting tissue repair and inflammation resolution (research claims).
Clinical evidence: No robust FDA-reviewed trials for the combination; evidence is from compounding-pharmacy literature. The individual components have preclinical research; the combination is not FDA-approved.
Compounded combination, not FDA-approved. Composition varies by pharmacy; not FDA-reviewed for safety or efficacy.